Applied Biology, Inc.
🇺🇸United States
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Phase 3
Not yet recruiting
- Conditions
- Chemotherapy Induced AlopeciaChemotherapy Side Effects
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06762548
- Locations
- 🇮🇹
University of Rome ("G. Marconi"), Rome, Italy
Clinical Study of CS-001 As a Treatment for Canities (Grey Hair)
Phase 3
Not yet recruiting
- Conditions
- CanitiesGrey Hair
- Interventions
- Drug: Placebo Topical Solution
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT06745336
Clinical Study of DA-001 As a Treatment for Telogen Effluvium
Phase 3
Not yet recruiting
- Conditions
- Telogen Effluvium
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT06648850
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Phase 3
Not yet recruiting
- Conditions
- Androgenetic AlopeciaFemale Pattern BaldnessMale Pattern Baldness
- Interventions
- Dietary Supplement: DA-005Other: Placebo Topical SolutionDietary Supplement: Placebo Oral Tablet
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 516
- Registration Number
- NCT06501924
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
Phase 3
Withdrawn
- Conditions
- Androgenetic AlopeciaFemale Pattern Baldness
- Interventions
- Dietary Supplement: Daniel Alain Probiotic Treatment for Androgenetic Alopecia
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT06484881
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
Not Applicable
Completed
- Conditions
- Hair DiseasesAlopeciaHair Loss
- Interventions
- Combination Product: DA-OTC-002
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06095739
- Locations
- 🇧🇷
Hospital Oscar Nicolau, Manaus, Brazil
Treatment for Post Acute COVID-19 Syndrome
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05507372
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT05016284
- Locations
- 🇧🇷
Centro Universitário Nilton Lins, Manaus, Amazonas, Brazil
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 602
- Registration Number
- NCT04986176
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
Phase 3
Withdrawn
- Conditions
- Covid19SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT04853927
- Locations
- 🇧🇷
Samel Hospital, Manaus, Amazonas, Brazil
© Copyright 2025. All Rights Reserved by MedPath